Review



rabbit polyclonal anti human enos  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Boster Bio rabbit polyclonal anti human enos
    Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic <t>eNOS</t> levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.
    Rabbit Polyclonal Anti Human Enos, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 44 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti human enos/product/Boster Bio
    Average 93 stars, based on 44 article reviews
    rabbit polyclonal anti human enos - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "NOSTRIN is an emerging negative regulator of decompensated cirrhotic patients with portal hypertension."

    Article Title: NOSTRIN is an emerging negative regulator of decompensated cirrhotic patients with portal hypertension.

    Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    doi: 10.1016/j.dld.2024.08.050

    Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic eNOS levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.
    Figure Legend Snippet: Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic eNOS levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.

    Techniques Used: Control, Expressing, Immunohistochemistry, Western Blot, Residue, Enzyme-linked Immunosorbent Assay



    Similar Products

    93
    Boster Bio rabbit polyclonal anti human enos
    Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic <t>eNOS</t> levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.
    Rabbit Polyclonal Anti Human Enos, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti human enos/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal anti human enos - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    90
    Becton Dickinson rabbit polyclonal anti-mouse/rat/human enos
    Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic <t>eNOS</t> levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.
    Rabbit Polyclonal Anti Mouse/Rat/Human Enos, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti-mouse/rat/human enos/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal anti-mouse/rat/human enos - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti human polyclonal enos antibody
    In vitro assessment of left ventricular endothelial nitric oxide synthase <t>(eNOS)</t> and NO bioavailability in Normal and DM + HFD + CKD swine. Left ventricular endothelial eNOS mRNA ( a ) and protein ( b ) levels, as well as phosphorylation (p-eNOS) at the Ser1177 site ( c ) were not different between groups, while p-eNOS at the inhibitory Thr495 site was lower in DM + HFD + CKD swine ( d ). No differences between groups in eNOS glutathionylation ( e ), coupling ( f ), myocardial nitric oxide metabolites nitrite (NO 2 − ) and nitrate (NO 3 − , g ) and the ratio of phosphorylated to non-phosphorylated vasodilator activated phosphoprotein (p-VASP/VASP, h ) were observed. Values are mean ± SEM. The original western blots are available in the online supplemental file: original eNOS and p-eNOS (Ser1177) western blots are shown in Supplementary Fig. 6, p-eNOS (Thr495), VASP and p-VASP blots are shown in Supplementary Fig. 7, Glutathione/eNOS blots are shown in Supplementary Fig. 8, and eNOS monomer/dimer blots are shown in Supplementary Fig. 9. * P < 0.05 for DM + HFD + CKD versus Normal by Student’s t test
    Rabbit Anti Human Polyclonal Enos Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti human polyclonal enos antibody/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    rabbit anti human polyclonal enos antibody - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    90
    Affinity Biosciences polyclonal rabbit anti- human nos3
    In vitro assessment of left ventricular endothelial nitric oxide synthase <t>(eNOS)</t> and NO bioavailability in Normal and DM + HFD + CKD swine. Left ventricular endothelial eNOS mRNA ( a ) and protein ( b ) levels, as well as phosphorylation (p-eNOS) at the Ser1177 site ( c ) were not different between groups, while p-eNOS at the inhibitory Thr495 site was lower in DM + HFD + CKD swine ( d ). No differences between groups in eNOS glutathionylation ( e ), coupling ( f ), myocardial nitric oxide metabolites nitrite (NO 2 − ) and nitrate (NO 3 − , g ) and the ratio of phosphorylated to non-phosphorylated vasodilator activated phosphoprotein (p-VASP/VASP, h ) were observed. Values are mean ± SEM. The original western blots are available in the online supplemental file: original eNOS and p-eNOS (Ser1177) western blots are shown in Supplementary Fig. 6, p-eNOS (Thr495), VASP and p-VASP blots are shown in Supplementary Fig. 7, Glutathione/eNOS blots are shown in Supplementary Fig. 8, and eNOS monomer/dimer blots are shown in Supplementary Fig. 9. * P < 0.05 for DM + HFD + CKD versus Normal by Student’s t test
    Polyclonal Rabbit Anti Human Nos3, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit anti- human nos3/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    polyclonal rabbit anti- human nos3 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Cayman Chemical anti-human enos rabbit polyclonal antibody
    In vitro assessment of left ventricular endothelial nitric oxide synthase <t>(eNOS)</t> and NO bioavailability in Normal and DM + HFD + CKD swine. Left ventricular endothelial eNOS mRNA ( a ) and protein ( b ) levels, as well as phosphorylation (p-eNOS) at the Ser1177 site ( c ) were not different between groups, while p-eNOS at the inhibitory Thr495 site was lower in DM + HFD + CKD swine ( d ). No differences between groups in eNOS glutathionylation ( e ), coupling ( f ), myocardial nitric oxide metabolites nitrite (NO 2 − ) and nitrate (NO 3 − , g ) and the ratio of phosphorylated to non-phosphorylated vasodilator activated phosphoprotein (p-VASP/VASP, h ) were observed. Values are mean ± SEM. The original western blots are available in the online supplemental file: original eNOS and p-eNOS (Ser1177) western blots are shown in Supplementary Fig. 6, p-eNOS (Thr495), VASP and p-VASP blots are shown in Supplementary Fig. 7, Glutathione/eNOS blots are shown in Supplementary Fig. 8, and eNOS monomer/dimer blots are shown in Supplementary Fig. 9. * P < 0.05 for DM + HFD + CKD versus Normal by Student’s t test
    Anti Human Enos Rabbit Polyclonal Antibody, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human enos rabbit polyclonal antibody/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    anti-human enos rabbit polyclonal antibody - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals polyclonal rabbit anti-human enos
    Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti <t>eNOS</t> (E,F) . Heterogenicity in fiber staining is clearly seen. Bar: 100 μm.
    Polyclonal Rabbit Anti Human Enos, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit anti-human enos/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    polyclonal rabbit anti-human enos - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Millipore enos (cat. no. sab4502013; polyclonal rabbit anti-human; 1:5,000
    Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti <t>eNOS</t> (E,F) . Heterogenicity in fiber staining is clearly seen. Bar: 100 μm.
    Enos (Cat. No. Sab4502013; Polyclonal Rabbit Anti Human; 1:5,000, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/enos (cat. no. sab4502013; polyclonal rabbit anti-human; 1:5,000/product/Millipore
    Average 90 stars, based on 1 article reviews
    enos (cat. no. sab4502013; polyclonal rabbit anti-human; 1:5,000 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc rabbit anti-human phosphorylated (thr 495 ) enos polyclonal antibody
    Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti <t>eNOS</t> (E,F) . Heterogenicity in fiber staining is clearly seen. Bar: 100 μm.
    Rabbit Anti Human Phosphorylated (Thr 495 ) Enos Polyclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti-human phosphorylated (thr 495 ) enos polyclonal antibody/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    rabbit anti-human phosphorylated (thr 495 ) enos polyclonal antibody - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology anti human nos3 rabbit polyclonal antibody
    Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti <t>eNOS</t> (E,F) . Heterogenicity in fiber staining is clearly seen. Bar: 100 μm.
    Anti Human Nos3 Rabbit Polyclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human nos3 rabbit polyclonal antibody/product/Santa Cruz Biotechnology
    Average 94 stars, based on 1 article reviews
    anti human nos3 rabbit polyclonal antibody - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic eNOS levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.

    Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    Article Title: NOSTRIN is an emerging negative regulator of decompensated cirrhotic patients with portal hypertension.

    doi: 10.1016/j.dld.2024.08.050

    Figure Lengend Snippet: Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic eNOS levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.

    Article Snippet: Tissues were incubated with 5 % goat s t s ( t o r a H m ( t c s 2 f a a u R t e R A i ( A a w r i P t m 2 t p ( s t ( p R a t ( t i w i a ( H t a 2 t s a s S t l ( P 3 3 a c w t i t s p o B 3 a a erum for 1 hr and incubated overnight at 4 °C with primary anibodies against rabbit polyclonal anti-human Nostrin (1:100; cat: c-134,803, Santacruz) and rabbit polyclonal anti- human eNOS 1:100; cat: PA-1712–1, Bosterbio).

    Techniques: Control, Expressing, Immunohistochemistry, Western Blot, Residue, Enzyme-linked Immunosorbent Assay

    In vitro assessment of left ventricular endothelial nitric oxide synthase (eNOS) and NO bioavailability in Normal and DM + HFD + CKD swine. Left ventricular endothelial eNOS mRNA ( a ) and protein ( b ) levels, as well as phosphorylation (p-eNOS) at the Ser1177 site ( c ) were not different between groups, while p-eNOS at the inhibitory Thr495 site was lower in DM + HFD + CKD swine ( d ). No differences between groups in eNOS glutathionylation ( e ), coupling ( f ), myocardial nitric oxide metabolites nitrite (NO 2 − ) and nitrate (NO 3 − , g ) and the ratio of phosphorylated to non-phosphorylated vasodilator activated phosphoprotein (p-VASP/VASP, h ) were observed. Values are mean ± SEM. The original western blots are available in the online supplemental file: original eNOS and p-eNOS (Ser1177) western blots are shown in Supplementary Fig. 6, p-eNOS (Thr495), VASP and p-VASP blots are shown in Supplementary Fig. 7, Glutathione/eNOS blots are shown in Supplementary Fig. 8, and eNOS monomer/dimer blots are shown in Supplementary Fig. 9. * P < 0.05 for DM + HFD + CKD versus Normal by Student’s t test

    Journal: Basic Research in Cardiology

    Article Title: Reduced nitric oxide bioavailability impairs myocardial oxygen balance during exercise in swine with multiple risk factors

    doi: 10.1007/s00395-021-00890-8

    Figure Lengend Snippet: In vitro assessment of left ventricular endothelial nitric oxide synthase (eNOS) and NO bioavailability in Normal and DM + HFD + CKD swine. Left ventricular endothelial eNOS mRNA ( a ) and protein ( b ) levels, as well as phosphorylation (p-eNOS) at the Ser1177 site ( c ) were not different between groups, while p-eNOS at the inhibitory Thr495 site was lower in DM + HFD + CKD swine ( d ). No differences between groups in eNOS glutathionylation ( e ), coupling ( f ), myocardial nitric oxide metabolites nitrite (NO 2 − ) and nitrate (NO 3 − , g ) and the ratio of phosphorylated to non-phosphorylated vasodilator activated phosphoprotein (p-VASP/VASP, h ) were observed. Values are mean ± SEM. The original western blots are available in the online supplemental file: original eNOS and p-eNOS (Ser1177) western blots are shown in Supplementary Fig. 6, p-eNOS (Thr495), VASP and p-VASP blots are shown in Supplementary Fig. 7, Glutathione/eNOS blots are shown in Supplementary Fig. 8, and eNOS monomer/dimer blots are shown in Supplementary Fig. 9. * P < 0.05 for DM + HFD + CKD versus Normal by Student’s t test

    Article Snippet: Blots were probed with a mouse anti-human glutathione monoclonal antibody (1:1000, MA1-7620, Invitrogen) and a rabbit anti-human polyclonal eNOS antibody (1:1000, 9572, Cell Signalling Technology Inc.).

    Techniques: In Vitro, Phospho-proteomics, Western Blot

    In vitro assessment of left ventricular NO bioavailability and oxidative stress in Normal and DM + HFD + CKD swine. Left ventricular myocardial nitrite (NO 2 − ) and nitrate (NO 3 − ) levels plotted as a function of eNOS protein levels ( a ), left ventricular 8-isoprostane levels ( b ), NADPH-oxidase 2 (NOX2) mRNA expression levels ( c ) left ventricular total antioxidant capacity ( d ), and in vitro small coronary artery endothelium-dependent vasodilation to bradykinin (BK) in the absence/presence of ROS scavengers Tempol and MPG ( e and f ) in Normal and DM + HFD + CKD swine. Values are mean ± SEM. * P < 0.05 and (*) P = 0.086 for DM + HFD + CKD versus Normal by logistic regression analysis ( a ), Student’s t test ( b–d ) and two-way ANOVA for repeated measures ( f )

    Journal: Basic Research in Cardiology

    Article Title: Reduced nitric oxide bioavailability impairs myocardial oxygen balance during exercise in swine with multiple risk factors

    doi: 10.1007/s00395-021-00890-8

    Figure Lengend Snippet: In vitro assessment of left ventricular NO bioavailability and oxidative stress in Normal and DM + HFD + CKD swine. Left ventricular myocardial nitrite (NO 2 − ) and nitrate (NO 3 − ) levels plotted as a function of eNOS protein levels ( a ), left ventricular 8-isoprostane levels ( b ), NADPH-oxidase 2 (NOX2) mRNA expression levels ( c ) left ventricular total antioxidant capacity ( d ), and in vitro small coronary artery endothelium-dependent vasodilation to bradykinin (BK) in the absence/presence of ROS scavengers Tempol and MPG ( e and f ) in Normal and DM + HFD + CKD swine. Values are mean ± SEM. * P < 0.05 and (*) P = 0.086 for DM + HFD + CKD versus Normal by logistic regression analysis ( a ), Student’s t test ( b–d ) and two-way ANOVA for repeated measures ( f )

    Article Snippet: Blots were probed with a mouse anti-human glutathione monoclonal antibody (1:1000, MA1-7620, Invitrogen) and a rabbit anti-human polyclonal eNOS antibody (1:1000, 9572, Cell Signalling Technology Inc.).

    Techniques: In Vitro, Expressing

    Proposed mechanisms contributing to coronary microvascular dysfunction in DM + HFD + CKD swine. NOS, nitric oxide synthase; PDE5, phosphodiesterase 5; NO, nitric oxide, eNOS, endothelial nitric oxide synthase; cGMP, cyclic guanosine monophosphate; TNFα, tumor necrosis factor α; ROS, reactive oxygen species

    Journal: Basic Research in Cardiology

    Article Title: Reduced nitric oxide bioavailability impairs myocardial oxygen balance during exercise in swine with multiple risk factors

    doi: 10.1007/s00395-021-00890-8

    Figure Lengend Snippet: Proposed mechanisms contributing to coronary microvascular dysfunction in DM + HFD + CKD swine. NOS, nitric oxide synthase; PDE5, phosphodiesterase 5; NO, nitric oxide, eNOS, endothelial nitric oxide synthase; cGMP, cyclic guanosine monophosphate; TNFα, tumor necrosis factor α; ROS, reactive oxygen species

    Article Snippet: Blots were probed with a mouse anti-human glutathione monoclonal antibody (1:1000, MA1-7620, Invitrogen) and a rabbit anti-human polyclonal eNOS antibody (1:1000, 9572, Cell Signalling Technology Inc.).

    Techniques:

    Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti eNOS (E,F) . Heterogenicity in fiber staining is clearly seen. Bar: 100 μm.

    Journal: Frontiers in Pharmacology

    Article Title: Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

    doi: 10.3389/fphar.2017.00196

    Figure Lengend Snippet: Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti eNOS (E,F) . Heterogenicity in fiber staining is clearly seen. Bar: 100 μm.

    Article Snippet: Sections were then incubated overnight at 4°C with the following antibodies: monoclonal mouse anti-human connexin-43 (1:800; Santa Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal rabbit anti-human eNOS (1:50; Novus Biologicals).

    Techniques: Immunohistochemistry, Injection, Saline, Staining

    (A) Representative immunoblots for connexin-43 protein expression in whole cardiac left ventricle. Diagram bars show the results of densitometric analysis of connexin-43 in whole cardiac left ventricle. Homogenized samples from heart show essentially the connexin-43 in its phosphorylated form (strongest bands for the quantification) (B) Quantitative analysis of connexin-43 mRNA levels in whole cardiac left ventricle. (C) Representative immunoblots for eNOS protein expression. Diagram bars show the results of densitometric analysis of eNOS in whole cardiac left ventricle. (D) Quantitative analysis of eNOS mRNA levels in whole cardiac left ventricle Data are presented as means ± SEM of observations obtained for 5–8 tissue samples from 5 to 8 animals per treatment. A one-way ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical analysis ( ∗ P < 0.05, CPT 2 mg/kg vs. control, ∗∗∗ P < 0.001, CPT 2 mg/kg vs. control, +++ P < 0.001, CPT 3 mg/kg vs. control, $ P < 0.05, CPT 3 mg/kg vs. CPT 2 mg/Kg, $$ P < 0.01, CPT 3 mg/kg vs. CPT 2 mg/Kg).

    Journal: Frontiers in Pharmacology

    Article Title: Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

    doi: 10.3389/fphar.2017.00196

    Figure Lengend Snippet: (A) Representative immunoblots for connexin-43 protein expression in whole cardiac left ventricle. Diagram bars show the results of densitometric analysis of connexin-43 in whole cardiac left ventricle. Homogenized samples from heart show essentially the connexin-43 in its phosphorylated form (strongest bands for the quantification) (B) Quantitative analysis of connexin-43 mRNA levels in whole cardiac left ventricle. (C) Representative immunoblots for eNOS protein expression. Diagram bars show the results of densitometric analysis of eNOS in whole cardiac left ventricle. (D) Quantitative analysis of eNOS mRNA levels in whole cardiac left ventricle Data are presented as means ± SEM of observations obtained for 5–8 tissue samples from 5 to 8 animals per treatment. A one-way ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical analysis ( ∗ P < 0.05, CPT 2 mg/kg vs. control, ∗∗∗ P < 0.001, CPT 2 mg/kg vs. control, +++ P < 0.001, CPT 3 mg/kg vs. control, $ P < 0.05, CPT 3 mg/kg vs. CPT 2 mg/Kg, $$ P < 0.01, CPT 3 mg/kg vs. CPT 2 mg/Kg).

    Article Snippet: Sections were then incubated overnight at 4°C with the following antibodies: monoclonal mouse anti-human connexin-43 (1:800; Santa Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal rabbit anti-human eNOS (1:50; Novus Biologicals).

    Techniques: Western Blot, Expressing, Control

    Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat aorta. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti eNOS antibody (C,D) . Bar: 100 μm.

    Journal: Frontiers in Pharmacology

    Article Title: Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

    doi: 10.3389/fphar.2017.00196

    Figure Lengend Snippet: Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat aorta. Rats were injected intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week −1 , right column). Histological samples embedded in paraffin and stained with Masson’s trichrome (A,B) . Samples processed for immunohistochemistry with anti eNOS antibody (C,D) . Bar: 100 μm.

    Article Snippet: Sections were then incubated overnight at 4°C with the following antibodies: monoclonal mouse anti-human connexin-43 (1:800; Santa Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal rabbit anti-human eNOS (1:50; Novus Biologicals).

    Techniques: Immunohistochemistry, Injection, Saline, Staining

    (A) Representative immunoblots for eNOS protein expression in aorta. Diagram bars show the result of densitometric analysis of eNOS in aorta. (B) Quantitative analysis of eNOS mRNA levels in aorta. (C) Representative immunoblots for plasminogen activator inhibitor-1 (PAI-1) protein expression in aorta. Diagram bars show the result of densitometric analysis of PAI-1 in aorta. Data are presented as means ± SEM of observations obtained for 5–8 tissue samples from 5 to 8 animals per treatment. A one-way ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical analysis.

    Journal: Frontiers in Pharmacology

    Article Title: Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

    doi: 10.3389/fphar.2017.00196

    Figure Lengend Snippet: (A) Representative immunoblots for eNOS protein expression in aorta. Diagram bars show the result of densitometric analysis of eNOS in aorta. (B) Quantitative analysis of eNOS mRNA levels in aorta. (C) Representative immunoblots for plasminogen activator inhibitor-1 (PAI-1) protein expression in aorta. Diagram bars show the result of densitometric analysis of PAI-1 in aorta. Data are presented as means ± SEM of observations obtained for 5–8 tissue samples from 5 to 8 animals per treatment. A one-way ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical analysis.

    Article Snippet: Sections were then incubated overnight at 4°C with the following antibodies: monoclonal mouse anti-human connexin-43 (1:800; Santa Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal rabbit anti-human eNOS (1:50; Novus Biologicals).

    Techniques: Western Blot, Expressing